SCHEMBL7299264

SCHEMBL7299264

CCN1CCN(CCCl)C1=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 5/20 0.33
KCNH2 Q12809 4/20 0.33
PER2 O15055 3/20 0.33
F2 P00734 1/20 0.33
ELANE P08246 1/20 0.33
CTSG P08311 1/20 0.33
CTRC Q99895 1/20 0.33
CRY2 Q49AN0 1/20 0.33
DRD2 P14416 3/20 0.32
ALOX15 P16050 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
LMNA P02545 1/20 0.31
GAA P10253 1/20 0.30
HTT P42858 1/20 0.30
POLB P06746 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
KMT2A Q03164 1/20 0.30
BCHE P06276 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7298365 0.88 BCHE (0.34) DRD3KCNH2PER2F2ELANE
SCHEMBL8112327 0.87 L3MBTL1 (0.37) DRD3KCNH2DRD2LMNAPOLB
SCHEMBL7298372 0.86 BCHE (0.36) DRD3KCNH2PER2F2ELANE
SCHEMBL329869 0.83 F2 (0.45) PER2F2ELANECTSGCTRC
SCHEMBL7414777 0.83 MEN1 (0.39) SMN1; SMN2GAAKMT2ABCHEACHE
SCHEMBL4423724 0.82 L3MBTL1 (0.39) DRD3KCNH2PER2F2ELANE
SCHEMBL19817111 0.80 GBA1 (0.42) BCHEACHE
SCHEMBL7410373 0.80 PER2 (0.34) DRD3KCNH2PER2CRY2DRD2
SCHEMBL10851707 0.78 PER2 (0.33) DRD3KCNH2PER2F2ELANE
SCHEMBL22604425 0.78 PER2 (0.36) PER2F2ELANECTSGCTRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2785717-B1 PYRAZOLOPYRROLIDINE COMPOUNDS NOVARTIS AG (CH) 2016-01-13 EP disclosed
US-8969341-B2 Pyrazolopyrrolidine compounds NOVARTIS AG (CH) 2015-03-03 US disclosed
US-20140350010-A1 Pyrazolopyrrolidine Compounds NOVARTIS AG (CH) 2014-11-27 US disclosed
EP-2785717-A1 PYRAZOLOPYRROLIDINE COMPOUNDS Novartis AG (CH) 2014-10-08 EP disclosed
WO-2013080141-A1 Pyrazolopyrrolidine compounds NOVARTIS AG (CH) 2013-06-06 WO disclosed
EP-0309043-B1 Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides JANSSEN PHARMACEUTICA NV (BE) 1994-11-09 EP disclosed
US-5041454-A Stimulate gastrointestinal motility JANSSEN PHARMACEUTICA N.V. (BE) 1991-08-20 US disclosed
US-4975439-A Gastrointestinal motility stimulating properties JANSSEN PHARMACEUTICAL N.V. (BE) 1990-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350010-A1 Pyrazolopyrrolidine Compounds MDM4, MDM2, TP53 DRD3 4641/4885KCNH2 4059/4885PER2 3580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.